Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $360.67 Average PT from Brokerages

Posted by Francis Steltz on Aug 4th, 2026

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $360.6667.

Several research analysts have commented on KRYS shares. Evercore reissued an “outperform” rating and set a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th. Bank of America increased their target price on shares of Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Citigroup lifted their target price on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. HC Wainwright boosted their price target on shares of Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research note on Tuesday, June 16th. Finally, TD Cowen upped their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th.

Get Our Latest Report on KRYS

Key Stories Impacting Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

Positive Sentiment: Krystal reported diluted earnings of $1.79 per share, above the $1.73 consensus estimate and up from $1.29 a year earlier. Net income increased to $54.8 million, while VYJUVEK revenue rose 24% year over year to $119.2 million. Krystal Biotech Q2 earnings report
Positive Sentiment: VYJUVEK demand remained strong, with more than 730 reimbursement approvals and over 640 prescribers. The company expects launches in Spain and Italy before year-end and additional marketing applications in the second half of 2026. Krystal Biotech Announces Second Quarter Results
Positive Sentiment: The balance sheet remains strong, with $1.1 billion in cash and investments. Investors are also anticipating several pipeline milestones, including KB803 corneal-abrasion data in the fourth quarter and additional updates across respiratory, oncology and dermatology programs.
Neutral Sentiment: Management projected 2026 non-GAAP research and development plus selling, general and administrative expenses of $175 million to $195 million as VYJUVEK expands internationally. Krystal Biotech operating expense guidance
Negative Sentiment: Quarterly revenue of $119.2 million was below the approximately $121.8 million analyst forecast. That shortfall appears to have outweighed the EPS beat, particularly given KRYS’s premium valuation.
Negative Sentiment: SG&A expenses increased to $39.9 million from $35.1 million a year earlier. In addition, pricing and reimbursement negotiations in Germany and France may delay international revenue realization, with discussions extending into late 2026 and 2027. Krystal Biotech shares and revenue miss

Krystal Biotech Trading Down 8.4%

Shares of Krystal Biotech stock opened at $312.57 on Thursday. The firm has a market capitalization of $9.21 billion, a PE ratio of 41.79 and a beta of 0.53. Krystal Biotech has a 12 month low of $130.50 and a 12 month high of $382.54. The business’s 50-day moving average price is $339.96 and its 200-day moving average price is $296.59.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. As a group, analysts predict that Krystal Biotech will post 7.31 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the transaction, the insider directly owned 1,378,155 shares in the company, valued at $424,623,337.05. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the transaction, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 26,642 shares of company stock valued at $8,243,923. 13.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently made changes to their positions in the stock. Sound Income Strategies LLC increased its stake in shares of Krystal Biotech by 1,270.0% in the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after buying an additional 127 shares during the period. Western Wealth Management LLC purchased a new position in shares of Krystal Biotech in the first quarter valued at about $34,000. Greenline Wealth Management LLC purchased a new position in shares of Krystal Biotech in the fourth quarter valued at about $34,000. Danske Bank A S bought a new position in shares of Krystal Biotech during the third quarter valued at about $35,000. Finally, UMB Bank n.a. boosted its holdings in shares of Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

(Get Free Report)

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.